Physician profile

Elizabeth Compton Mitchell

Family Health · Cincinnati, OH

NPI 1780191197

$318.45

in general payments reported to CMS, 2019-2025

9 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$232.09

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Corium, LLC $106.18 2023-2024 Azstarys
Pfizer INC. $45.35 2021-2023
Neurelis, INC. $38.37 2023 Valtoco
Takeda Pharmaceuticals U.S.A., INC. $34.35 2022
Neos Therapeutics, LP $29.37 2023 Cotempla Xr-Odt
Sanofi-Aventis U.S. LLC $21.17 2023
Astrazeneca Pharmaceuticals LP $17.19 2023 Flumist Quadrivalent
Ironshore Pharmaceuticals INC. $13.91 2022
Tris Pharma INC $12.56 2022

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Elizabeth Compton Mitchell

$318.45

in general payments reported 2019-2025

Years
2021-2024
Top company
Corium, LLC

https://glasscript.com/doctor/11425558/elizabeth-compton-mitchell

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.